Clinical Trial Update: Gemcitabine Plus Erlotinib in RASH-positive Patients With Metastatic Pancreatic Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating Gemcitabine plus Erlotinib in rash-positive patients with metastatic pancreatic cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Gemzar (gemcitabine)
• Tarceva (erlotinib)

Snippet

Sponsor: Ludwig-Maximilians - University of Munich | Conditions: Metastatic Pancreatic Adenocarcinoma | Phase 2 | Status: UNKNOWN